Asthma

Ask a question or start a discussion
NEW TREATMENT ADDED BY A MEMBER
9 Studies
Inhaled steroids
These steroids are used to control and prevent asthma.
77% of users reported improvements
Prescription
TRIED
TRYING
How effective is it?
REMOVE ANSWER
completely cured
significant improvement
minor improvement
no difference
worse than before
Helps with prevention
0 (0%)
6 (46%)
4 (31%)
2 (15%)
1 (8%)
ESSENTIAL RESEARCH
A large-scale, consortium-based genomewide association study of asthma.
Asthma is genetically heterogeneous. A few common alleles are associated with disease risk at all ages. Implicated genes suggest a role for communication of epithelial damage to the adaptive immune system and activation of airway inflammation. Variants at the ORMDL3/GSDMB locus are associated only with childhood-onset disease. Elevation of total serum IgE levels has a minor role in the development of asthma. (Funded by the European Commission and others.)
...see more
READ MORE
0REPLY
NEW SYMPTOM ADDED BY A MEMBER
Yes
1
No
0
Wheezing
100% reported this symptom
A continuous, coarse, whistling sound produced in the respiratory airways during breathing.
CLINICAL TRIALCompleted
General Risk Factors and Inflammatory Determinants in Older Patients With Asthma
Rotterdam, Netherlands
All genders
A cross-sectional study in asthma patients to determine if a late age of onset asthma (start symptoms >18 years old), is associated with more persistent airway/systemic inflammation, worse asthma control, more co-morbidity, a different microbiome and poorer quality of life despite the use of optimized asthma therapy.
...see more
LEARN MORE
0REPLY1 YEAR AGO
ESSENTIAL RESEARCH
Lebrikizumab treatment in adults with asthma.
Lebrikizumab treatment was associated with improved lung function. Patients with high pretreatment levels of serum periostin had greater improvement in lung function with lebrikizumab than did patients with low periostin levels. (Funded by Genentech; ClinicalTrials.gov number, NCT00930163 .).
READ MORE
0REPLY
ESSENTIAL RESEARCH
An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications.
In the setting of chronic inflammatory airway disease including asthma, conventional tests such as FEV(1) reversibility or provocation tests are only indirectly associated with airway inflammation. Fe(NO) offers added advantages for patient care including, but not limited to (1) detecting of eosinophilic airway inflammation, (2) determining the likelihood of corticosteroid responsiveness, (3) monitoring of airway inflammation to determine the potential need for corticosteroid, and (4) unmasking of otherwise unsuspected nonadherence to corticosteroid therapy.
...see more
READ MORE
0REPLY
Get important Asthma updates delivered to your email.
NEW TREATMENT ADDED BY A MEMBER
20 Studies
Albuterol (salbutamol, ventolin)
Have any friends with asthma? You might see them with inhalers. These inhalers usually contain albuterol.
80% of users reported improvements
Prescription
TRIED
TRYING
How effective is it?
REMOVE ANSWER
completely cured
significant improvement
minor improvement
no difference
worse than before
Helps with prevention
0 (0%)
4 (40%)
4 (40%)
2 (20%)
0 (0%)
NEW SYMPTOM ADDED BY A MEMBER
Yes
1
No
0
Shortness of Breath (dyspnea)
100% reported this symptom
A feeling like one cannot breathe well enough.
ESSENTIAL RESEARCH
Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial.
Mepolizumab is an effective and well tolerated treatment that reduces the risk of asthma exacerbations in patients with severe eosinophilic asthma.
READ MORE
0REPLY
CLINICAL TRIALCompleted
Comparing Bronchodilation of Symbicort With and Without Valved Holding Chamber (Aerochamber Plus)
El Paso, United States
All genders
Phase 4
This study will compare the amount of bronchial tube relaxation from the Formoterol medicine contained in the Symbicort pressure Metered Dose Inhaler(pMDI)(a combination of Budesonide, a steroid, and Formoterol, a drug which relaxes the bronchial smooth muscle. The comparison will be using the pMDI in the usual fashion to the pMDIs and a spacer which allows more time for breathing in the medication. Breathing tests will be measured over a 12 hour period for the comparison.
...see more
LEARN MORE
0REPLY1 YEAR AGO
NEW TREATMENT ADDED BY A MEMBER
Avoid pollens or molds
Avoid sources of pollen/dust/mold.
67% of users reported improvements
Physical
Lifestyle
TRIED
TRYING
How effective is it?
REMOVE ANSWER
completely cured
significant improvement
minor improvement
no difference
worse than before
Helps with prevention
0 (0%)
2 (33%)
2 (33%)
2 (33%)
0 (0%)
ESSENTIAL RESEARCH
Exposure to environmental microorganisms and childhood asthma.
Children living on farms were exposed to a wider range of microbes than were children in the reference group, and this exposure explains a substantial fraction of the inverse relation between asthma and growing up on a farm. (Funded by the Deutsche Forschungsgemeinschaft and the European Commission.).
...see more
READ MORE
0REPLY
ESSENTIAL RESEARCH
Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision.
These are the most recent and currently the most systematically and transparently developed recommendations about the treatment of allergic rhinitis in adults and children. Patients, clinicians, and policy makers are encouraged to use these recommendations in their daily practice and to support their decisions.
...see more
READ MORE
0REPLY
ESSENTIAL RESEARCH
Dupilumab in persistent asthma with elevated eosinophil levels.
In patients with persistent, moderate-to-severe asthma and elevated eosinophil levels who used inhaled glucocorticoids and LABAs, dupilumab therapy, as compared with placebo, was associated with fewer asthma exacerbations when LABAs and inhaled glucocorticoids were withdrawn, with improved lung function and reduced levels of Th2-associated inflammatory markers. (Funded by Sanofi and Regeneron Pharmaceuticals; ClinicalTrials.gov number, NCT01312961.).
...see more
READ MORE
0REPLY
CLINICAL TRIALRecruiting
Functional Lung MRI for Early Treatment Response Assessment for Patients With Eosinophilic Asthma
Hanover, Germany
All genders
Patients with severe eosinophilic asthma will be placed on biologics if they continue to be uncontrolled despite maximized inhalation therapy or if they are only controlled under oral corticosteroids. Among biologics, 80% of patients respond to treatment and improve clinically, but approximately 20% are non-responders and up to date no established predictive factors for treatment response exist. Among the responders, about 30% respond very well (so-called super responders), the rest shows moderate improvements. As the lung function, one main criterion to evaluate treatment response improves in most patients with delay, the response (or non-response) to treatment can only be reliably estimated after 4 to 12 months. This can lead to prolonged use of medication in non-responders (overtreatment) on one hand and to unjustified and premature termination of therapy (undertreatment) on the other hand (GINA report 2019). Functional lung MRI has the potential to show early changes in lung microstructure, regional ventilation and perfusion and thus has the potential for early detection of therapy response. Very promising results of dynamic regional ventilation and perfusion mapping using phase resolved functional lung (PREFUL) MRI have been shown recently. However, if functional lung MRI can reliably detect treatment effects under Mepolizumab therapy and can help to predict a long-term patient outcome is still unknown. As these findings could directly influence clinical decision making this question is of high clinical relevance.
...see more
LEARN MORE
0REPLY1 YEAR AGO
ESSENTIAL RESEARCH
Airway microbiota and bronchial hyperresponsiveness in patients with suboptimally controlled asthma.
The composition of bronchial airway microbiota is associated with the degree of bronchial hyperresponsiveness among patients with suboptimally controlled asthma. These findings support the need for further functional studies to examine the potential contribution of members of the airway microbiota in asthma pathogenesis.
...see more
READ MORE
0REPLY
ABOUT
Asthma is a common long-term inflammatory disease of the airways of the lungs. It is characterized by variable and recurring symptoms, reversible airflow obstruction, and bronchospasm. Symptoms include episodes of wheezing, coughing, chest tightness, and shortness of breath. These episodes may occur a few times a day or a few times per week. Depending on the person, they may become worse at night or with exercise.Wikipedia
SHOW MORE
Get the latest Asthma research, treatments, and clinical trials in your email.